These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 15485406)

  • 1. Inclusion of albuminuria in hypertension and heart guidelines.
    Bakris G
    Kidney Int Suppl; 2004 Nov; (92):S124-5. PubMed ID: 15485406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subclinical Kidney Damage in Hypertensive Patients: A Renal Window Opened on the Cardiovascular System. Focus on Microalbuminuria.
    Mulè G; Castiglia A; Cusumano C; Scaduto E; Geraci G; Altieri D; Di Natale E; Cacciatore O; Cerasola G; Cottone S
    Adv Exp Med Biol; 2017; 956():279-306. PubMed ID: 27873229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microalbuminuria screening in patients with hypertension: recommendations for clinical practice.
    Volpe M
    Int J Clin Pract; 2008 Jan; 62(1):97-108. PubMed ID: 17971155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring and managing urinary albumin excretion: practical advice for primary care clinicians.
    Bakris GL; Kuritzky L
    Postgrad Med; 2009 Jul; 121(4):51-60. PubMed ID: 19641270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What is the evidence that microalbuminuria is a predictor of cardiovascular disease events?
    Yuyun MF; Adler AI; Wareham NJ
    Curr Opin Nephrol Hypertens; 2005 May; 14(3):271-6. PubMed ID: 15821422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The link between microalbuminuria, endothelial dysfunction and cardiovascular disease in diabetes.
    Naidoo DP
    Cardiovasc J S Afr; 2002; 13(4):194-9. PubMed ID: 12389063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Microalbuminuria and urinary albumin excretion: French guidelines].
    Halimi JM; Hadjadj S; Aboyans V; Allaert FA; Artigou JY; Beaufils M; Berrut G; Fauvel JP; Gin H; Nitenberg A; Renversez JC; Rusch E; Valensi P; Cordonnier D;
    Ann Biol Clin (Paris); 2008; 66(3):277-84. PubMed ID: 18558566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microalbuminuria and cardiovascular risk.
    Karalliedde J; Viberti G
    Am J Hypertens; 2004 Oct; 17(10):986-93. PubMed ID: 15485765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and CKD: a systematic review for a KDOQI clinical practice guideline.
    Slinin Y; Ishani A; Rector T; Fitzgerald P; MacDonald R; Tacklind J; Rutks I; Wilt TJ
    Am J Kidney Dis; 2012 Nov; 60(5):747-69. PubMed ID: 22999165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microalbuminuria as an early marker for cardiovascular disease.
    de Zeeuw D; Parving HH; Henning RH
    J Am Soc Nephrol; 2006 Aug; 17(8):2100-5. PubMed ID: 16825327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macroalbuminuria and microalbuminuria: do both predict renal and cardiovascular events with similar strength?
    de Jong PE; Gansevoort RT; Bakker SJ
    J Nephrol; 2007; 20(4):375-80. PubMed ID: 17879201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
    Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
    Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Twelve shifting paradigms in diabetic renal disease and hypertension.
    Mogensen CE
    Diabetes Res Clin Pract; 2008 Nov; 82 Suppl 1():S2-9. PubMed ID: 18947897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of subclinical organ damage for risk assessment and treatment in the hypertensive patient: role of microalbuminuria.
    Pontremoli R; Leoncini G; Viazzi F; Ratto E; Vaccaro V; Falqui V; Parodi A; Conti N; Tomolillo C; Deferrari G
    J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S112-4. PubMed ID: 16565232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microalbuminuria: a useful marker of cardiovascular disease.
    Jarraya F; Lakhdar R; Kammoun K; Mahfoudh H; Drissa H; Kammoun S; Abid M; Hachicha J
    Iran J Kidney Dis; 2013 May; 7(3):178-86. PubMed ID: 23689147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New insights into the significance of microalbuminuria.
    MacIsaac RJ; Jerums G; Cooper ME
    Curr Opin Nephrol Hypertens; 2004 Jan; 13(1):83-91. PubMed ID: 15090864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microalbuminuria and cardiovascular disease.
    Weir MR
    Clin J Am Soc Nephrol; 2007 May; 2(3):581-90. PubMed ID: 17699466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microalbuminuria: do we need a new threshold?
    Zamora CR; Cubeddu LX
    J Hum Hypertens; 2009 Feb; 23(2):146-9. PubMed ID: 18784737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Albuminuria as a predictor of cardiovascular and renal outcomes in people with known atherosclerotic cardiovascular disease.
    Mann JF; Yi QL; Gerstein HC
    Kidney Int Suppl; 2004 Nov; (92):S59-62. PubMed ID: 15485420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.